• Contact Us

The Full ASGCT 27th Annual Meeting Abstracts Collection is NOW LIVE! Click here to read the full collection.

• Annual Meeting
  • Register
  • Sponsor & Exhibit
  • Future Annual Meetings
  • Annual Meeting Archives

  • Program
    • Workshops
    • Schedule at a Glance

  • Abstracts
    • Submit
    • Present
    • Awards
    • Topics
• Membership
  • My Profile
  • Member Dashboard
  • Awards
  • Scientific Committees

  • Become a Member
  • Career Center
  • Membership Directory
  • Standing Committees

  • Economy-Based Rates
  • New Investigator Center of Educational Resources (NICER)
  • Elections
  • Volunteer
• Events
  • 2024 Advancing Gene and Cell Therapies for Cancer
    • Program
  • Platform Q + ASGCT: Application and Consideration of Treatment Strategies for Relapsed/Refractory MM
  • FDA & ASGCT: Immune Responses to AAV Vectors
  • Community Lunch & Learns

  • ASGCT Annual Meeting
  • Cell Press Webinar: Advances in Viral Vector Gene Delivery for CT Biomanufacturing
  • Policy Summit
  • Professional Development Cafés
  • Non-ASGCT Events

  • Around the World: Innovation in Japan
  • Molecular Therapy Presents: Targets and Biomarkers
  • ASGCT Insights
    • Past Sessions
• Awards
  • Annual Meeting Awards
    • Outstanding Achievement Award
    • Outstanding New Investigator Awards
    • George Stamatoyannopoulos Mentorship Award
    • Award for Excellence in Advancing Diversity, Equity, and Inclusion
    • Exemplary Service Award

  • Career Development Awards
  • Congressional Policy Fellowship

  • Diversity, Equity, & Inclusion Awards
  • Mavis Agbandje-McKenna Scholarship and Fund
• Outreach
  • Clinical Trials Finder
  • Community Quick Takes
    • Informed Consent
    • State of the Field Highlights + Approvals for CGT in 2023
  • Diversity, Equity, and Inclusion
  • Global Outreach
    • Global Gene Therapy Training Course

  • Patient Education: Gene Therapy 101
    • Gene Therapy Basics
    • Gene Therapy Approaches
    • Clinical Trials Process
    • Vectors 101
    • Gene Editing

  • Patient Education: Condition Treatments
    • Beta Thalassemia & Other Blood Disorders
    • CALD and MLD
    • Spinal Muscular Atrophy
    • CAR-T Basics
    • Hemophilia
• Publications
  • ASGCT Blog
  • PlatformQ + ASGCT: Can Gene Therapy Transform the Lives of Patients with GSD1a?
  • The Vector
    • The Vector Archive
  • Landscape Report

  • ASGCT Podcast Network
    • Giants of Gene Therapy
    • The Issue
    • The Molecular Therapy Podcast
  • The Advocate
    • Subscribe to The Advocate

  • Molecular Therapy Family
    • Molecular Therapy Presents Targets and Biomarkers
    • Cell Press Webinar: Advances in Viral Vector Gene Delivery for CT Biomanufacturing
    • Molecular Therapy
    • MT Methods & Clinical Development
    • MT Nucleic Acids
    • MT Oncology
• Advocacy
  • Events and Opportunities
    • Policy Summit
    • ASGCT-FDA Liaison Meeting
    • Cell + Gene Therapy Science Series
    • Congressional Policy Fellowship
    • FDA & ASGCT: Immune Responses to AAV Vectors

  • Policy Priorities
    • Patient Access Overview
    • Regulatory Policy
    • Research Funding

  • The Advocate
    • Subscribe to The Advocate
  • Policy Statements & Letters
• About
  • Leadership
    • Board of Directors
    • Scientific Committees
    • Standing Committees
    • Staff

  • Media
  • Our Culture
  • Strategic Plan
  • Meeting Code of Conduct
  • Terms and Conditions

  • Mission & Vision
    • Bylaws
  • Support ASGCT
    • Annual Meeting Support
    • Advertise in ASGCT Publications
    • Digital Programs
    • Giving
    • Year-Round Support

2021 Archive

Read and Download 2021 Reports

Learn about new approvals and the state of the field for each quarter of 2021.

Q4 2021

Globally, there are now 3,483 gene, cell, and RNA therapies in development from preclinical through pre-registration stages. Q4 2021 highlights: approval of a new cell therapy and a new RNA therapy in the U.S., and much more!

Read the Report

Q3 2021

New in Q3: two new gene therapies in the European Union (EU) and China, the expansion of two gene therapy approvals to new regions (South Korea and the EU), the continued growth ingene therapy research, and the latest on RNA therapeutic studies of anti-infective prophylactic vaccines.

Read the Report

Q2 2021

Highlights in the second quarter of 2021 include the approval of a new gene therapy in Japan, the expansion of gene therapy approvals to three new countries, and more!

Read the Report

Q1 2021

The data show unequivocally that gene, cell, and RNA therapies continue to grow rapidly with nearly 3,500 therapies in preclinical and clinical development throughout the world.

Read the Report